Predicting Success in the Biotech and Pharma Sectors Mark Schoenebaum of ISI Group earned two top spots on this year's All-America Research Team. Here he explains how he differentiates the good stocks from the bad. Related Articles One of Venture Capital’s Top Firms Just Raised Its Final Fund. Why Is That So Rare? Julie Segal Premium Biopharma Hedge Funds Rebounded Sharply Last Month — But Is It Sustainable? Stephen Taub Private Equity’s Biggest Leap of Faith Isn’t NAV Finance Sponsored by 17Capital